Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells

Abstract From the Canadian patent

A method of preferentially delivering an active agent to an immune cell such , as a myeloid progenitor cell, a dendritic cell a monocyte, a macrophage or a , T-lymphocyte or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent such , as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent. The other cell type that is infected with or suspectible to infection with an infectious agent …